NUVL Stock Overview
A clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Nuvalent, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$94.93 |
| 52 Week High | US$113.51 |
| 52 Week Low | US$61.02 |
| Beta | 1.33 |
| 11 Month Change | 4.66% |
| 3 Month Change | 12.64% |
| 1 Year Change | 48.28% |
| 33 Year Change | 357.27% |
| 5 Year Change | n/a |
| Change since IPO | 406.29% |
Recent News & Updates
Recent updates
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
Nov 18
Nuvalent: Promising Data Keeps Validating Pipeline And Platform
Sep 23Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation
Sep 17Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business
Aug 05Nuvalent: Making Precise Progress In Its Oncology Pipeline
Jun 24Nuvalent: NVL-655 Could Bring Blockbuster Potential
Jun 14Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Apr 22Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024
Feb 26Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?
Jan 07Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth
Sep 23Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Jun 10We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow
Feb 24Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Sep 13Nuvalent GAAP EPS of -$0.38 beats by $0.03
Aug 10Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
May 28We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
Oct 29Shareholder Returns
| NUVL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.3% | 2.5% | 2.2% |
| 1Y | 48.3% | 16.1% | 31.6% |
Return vs Industry: NUVL exceeded the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: NUVL exceeded the US Market which returned 31.6% over the past year.
Price Volatility
| NUVL volatility | |
|---|---|
| NUVL Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NUVL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NUVL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 127 | Jim Porter | www.nuvalent.com |
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Nuvalent, Inc. Fundamentals Summary
| NUVL fundamental statistics | |
|---|---|
| Market cap | US$6.75b |
| Earnings (TTM) | -US$224.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-30.1x
P/E RatioIs NUVL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUVL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$224.29m |
| Earnings | -US$224.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NUVL perform over the long term?
See historical performance and comparison